GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ranibizumab   Click here for help

GtoPdb Ligand ID: 6779

Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Approved drug
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.

Biosimilars:
Name(s)Trade nameCompanyClinical PhaseIndications
Razumab®Intas PharmaceuticalsApproved (India 2015)As per reference agent
SB11; ranibizumab-nunaByooviz®Samsung BioepisApproved (EMA & FDA 2021)As per reference agent
Susvimo®Genentech/RocheApproved (FDA 2021)wet AMD
FYB201; ranibizumab-eqrnCimerli®Coherus BioSciencesApproved (FDA 2022)As per reference agent
Ranivisio®Midas PharmaApproved (EMA 2022)wet AMD
Ximluci®STADA ArzneimittelApproved (EMA 2022)As per reference agent
ranibizumab biosimilarRimmyrah®Qilu PharmaApproved (EMA 2024)As per reference agent
Classification Click here for help
Compound class Antibody
Approved drug? Yes. US FDA (2006)  |  EU EMA (2007)
International Nonproprietary Names Click here for help
INN number INN
8313 ranibizumab
Synonyms Click here for help
Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 84
Reactome Drug Reactome logo R-ALL-9679464
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 178103385
PubChem SID 178103385
Search PubMed clinical trials ranibizumab
Search PubMed titles ranibizumab
Search PubMed titles/abstracts ranibizumab
Wikipedia Ranibizumab